The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
MASI will be acquired by Danaher for $9.9B in cash, sending shares soaring as the medtech firm prepares to join DHR's Diagnostics segment.
Masimo stock (MASI) has faced a challenging year, trailing the broader market with a -3% annual return. While shares surged 34% yesterday following news of an acquisition by Danaher, this spike only partially offsets a period of long-term stagnation.
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Catherine Szyman CEO | NASDAQ (NGS) Exchange | 574795100 CUSIP |
| US Country | 3,600 Employees | 11 Dec 2012 Last Dividend | - Last Split | 8 Aug 2007 IPO Date |
Masimo Corporation is a global leader in the development, manufacturing, and marketing of innovative patient monitoring technologies, automation, and connectivity solutions. Founded in 1989 and headquartered in Irvine, California, Masimo is dedicated to transforming patient care through its groundbreaking products and services. Its technologies are designed to improve patient outcomes and reduce the cost of care by solving the limitations of conventional monitoring systems. Masimo's extensive portfolio caters to hospitals, emergency medical services, home care providers, long-term care facilities, physician offices, veterinarians, and consumers, fulfilling the industry's demand for accurate, reliable, and accessible patient monitoring solutions.
Masimo Corporation offers an array of products and services underpinned by their proprietary technology platforms. These include: